Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer

Author:

Basho Reva K.1,Gilcrease Michael2,Murthy Rashmi K.3,Helgason Thorunn4,Karp Daniel D.4,Meric-Bernstam Funda5,Hess Kenneth R.6,Herbrich Shelley M.7,Valero Vicente3,Albarracin Constance2,Litton Jennifer K.3,Chavez-MacGregor Mariana8,Ibrahim Nuhad K.3,Murray James L.3,Koenig Kimberly B.3,Hong David4,Subbiah Vivek4,Kurzrock Razelle9,Janku Filip4,Moulder Stacy L.10

Affiliation:

1. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston

2. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston

3. Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston

4. Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston

5. Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston5Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston6Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston

6. Biostatistics, The University of Texas MD Anderson Cancer Center, Houston

7. Pediatrics, The University of Texas MD Anderson Cancer Center, Houston

8. Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston9Health Services Research, The University of Texas MD Anderson Cancer Center, Houston

9. Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston10Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, La Jolla

10. Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston4Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3